DOCSLIB.ORG

The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CLINICAL PRACTICE GUIDELINE The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management Guideline Committee Members (alpha order): Table of Contents Anika Alvanzo, MD, MS, DFASAM, FACP Kurt Kleinschmidt, MD, FASAM Glossary of Terms 2 Abbreviations and Acronyms 3 Julie A. Kmiec, DO, FASAM Executive Summary 3 George Kolodner, MD, DLFAPA, FASAM Introduction 15 Gerald E. Marti, MD, PhD I. Purpose 15 06/04/2020 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3RQIKUrpuF//+TLr8jGhDY87TpJTbZN0FK3a045zhsAU= by https://journals.lww.com/journaladdictionmedicine from Downloaded Downloaded William F. Murphy, DO, MS, DFASAM II. Background 15 Carlos F. Tirado, MD, FASAM III. Scope of Guideline 16 from IV. Intended Audience 16 Corey Waller, MD, MS, DFASAM, FACEP https://journals.lww.com/journaladdictionmedicine V. Qualifying Statement 16 Lewis S. Nelson, MD, FASAM, FACEP, FACMT (Chair) VI. Special Terms 16 Approach and Methodology 17 I. Overview of Approach 17 Clinical Champions (alpha order): II. Develop the Scope and Key Questions 18 Stephen Holt, MD, MS, FACP III. Conduct a Literature Review 18 Darius Rastegar, MD, FASAM IV. Develop Draft Guideline Statements 19 Richard Saitz, MD, MPH, FACP, DFASAM V. Conduct Panel Ratings 19 VI. Drafting the Guideline Document 20 Michael F. Weaver, MD, DFASAM Recommendations 20 by I. Identification and Diagnosis of Alcohol Withdrawal 20 BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3RQIKUrpuF//+TLr8jGhDY87TpJTbZN0FK3a045zhsAU= ASAM Quality Improvement Councilà (alpha order): A. Identification 20 B. Diagnosis 21 John Femino, MD, DFASAM C. Differential Diagnosis 21 Kenneth Freedman, MD, DFASAM (Chair) II. Initial Assessment of Alcohol Withdrawal 23 R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM A. General Approach 23 Barbara Herbert, MD, DFASAM (Past- Chair) B. Risk Factors for Severe or Complicated Withdrawal 24 C. Risk Assessment Tools 25 Margaret Jarvis, MD, DFASAM D. Symptom Assessment Scales 26 Margaret M. Kotz, DO, DFASAM E. Identify Concurrent Conditions 27 P. Stephen Novack, DO III. Level of Care Determination 28 David R. Pating, MD A. General Approach 28 Sandrine Pirard, MD, PhD, MPH, FAPA, FASAM B. Level of Care Determination Tools 28 C. Considerations for Ambulatory vs Inpatient Management 29 IV. Ambulatory Management of Alcohol Withdrawal 33 ASAM Staff: A. Monitoring 33 Maureen Boyle, PhD, Chief Quality and Science Officer B. Supportive Care 35 Leah White, MPH, Director of Quality Improvement C. AUD Treatment Initiation and Engagement 36 D. Pharmacotherapy 36 Taleen Safarian, Manager of Science and Dissemination V. Inpatient Management of Alcohol Withdrawal 43 A. Monitoring 43 Institute for Research Education and Training in Addic- B. Supportive Care 44 C. AUD Treatment Initiation and Engagement 45 tions (IRETA) Team Members: D. Pharmacotherapy 45 Dawn Lindsay, PhD, Project Director VI. Addressing Complicated Alcohol Withdrawal 50 Jessica Williams, MPH, Assistant Project Director A. Alcohol Withdrawal Seizure 50 Piper Lincoln, MS, Senior Research Associate B. Alcohol Withdrawal Delirium 51 C. Alcohol-Induced Psychotic Disorder 53 Jackie Jones, MS, Research Associate D. Resistant Alcohol Withdrawal 53 on 06/04/2020 Rachael Vargo, BA, Research Associate VII. Specific Settings and Populations 54 Peter F. Luongo, PhD, Executive Director A. Primary Care 54 B. Emergency Departments 55 C. Hospitalized Patients 56 ASAM is honored that this clinical practice guideline has D. Patients with Medical Conditions 58 been endorsed by: E. Patients who Take Opioids 58 American College of Preventive Medicine F. Patients who are Pregnant 58 American Osteopathic Academy of Addiction Medicine Areas for Further Research 59 Appendices 61 Federation of State Physician Health Programs I. Cited References 61 National Association of Addiction Treatment Providers II. Literature Search Methods 66 National Association of Clinical Nurse Specialists A. Empirical Literature Search Terms 66 National Commission on Correctional Health Care B. Gray Literature Search 66 Adopted by the ASAM Board of Directors January 23, 2020 1 Copyright © 2020 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited. ASAM CPG on Alcohol Withdrawal Management Adopted by the ASAM Board of Directors January 23, 2020 C. PRISMA Flow Diagram 67 CIWA-Ar: The Clinical Institute Withdrawal Assess- D. Reasons for Exclusion 68 III. Alcohol Withdrawal Scales Table 68 ment of Alcohol Scale, Revised, is a reliable, valid, and IV. Flowcharts (Supplemental Digital Content, 70 reproducible severity of alcohol withdrawal in communicative http://links.lww.com/JAM/A192) patients once a diagnosis has been made.2 V. Sample Medication Regimens 70 Complicated alcohol withdrawal: See Special Terms VI. Statement Rating Table (Supplemental Digital Content, 70 http://links.lww.com/JAM/A193) on page 16. VII. Disclosures and Conflicts of Interest 70 Clinicians (Healthcare providers): Used throughout A. 2019 Guideline Committee Member Relationships 70 the guideline, this term is intentionally broad. It encompasses with Industry and Other Entities anyone who participates in providing care to patients with B. 2019 ASAM Board of Directors Relationships 71 with Industry and Other Entities (Supplemental Digital substance use disorders, including staff at specialty addiction Content, http://links.lww.com/JAM/A194) treatment centers or other healthcare settings that provide C. 2019 ASAM Quality Improvement Council 71 substance use disorder treatment.3 (Oversight Committee) Relationships with Industry Fixed-dosing: See Special Terms on page 16. and Other Entities (Supplemental Digital Content, http://links.lww.com/JAM/A194) Front loading: See Special Terms on page 16. D. 2019 Clinical Champions Relationships with Industry 72 GABAergic agents: Drugs that affect the neurotrans- and Other Entities mitter GABA or its receptors. These include agonists, antag- E. 2020 External Reviewers Relationships with Industry and 72 onists, modulators, reuptake inhibitors and enzymes. Other Entities (Supplemental Digital Content, http://links.lww.com/JAM/A194) Examples include benzodiazepines, phenobarbital, and car- bamazepine. Inpatient Withdrawal Management: See Special Terms on page 16. GLOSSARY OF TERMS Kindling: The relationship between repeated episodes of alcohol withdrawal which become progressively more Below are terms that are used throughout the guideline. severe is referred to as the kindling effect or process.4 The Note that some terms listed below are used to convey a effect is theorized to be the result of increased neuronal specific meaning for the purposes of this guideline (e.g., excitability and sensitivity with repeated episodes of with- ‘‘clinicians’’). drawal and has been demonstrated to result in increased Abstinence: Intentional and consistent restraint from craving for alcohol and decreased responsiveness to treatment the pathological pursuit of reward and/or relief that involves with benzodiazepines.5–7 the use of substances and other behaviors. These behaviors may involve, but are not necessarily limited to substance use, Level of Care: See Special Terms on page 16. gambling, video gaming, or compulsive sexual behaviors. Use Monotherapy (see also adjunct therapy): The use of a of FDA approved medications for the treatment of substance single drug to treat a disorder or disease. use disorder is consistent with abstinence. Patients: Used throughout the guideline, this term is Addiction Specialist Physician: Addiction specialist intentionally broad. It encompasses anyone who receives care for a Substance Use Disorder (SUD) in a specialty SUD physicians include addiction medicine physicians and addic- 3 tion psychiatrists who hold either a subspecialty board certi- treatment center or other healthcare setting. fication in addiction medicine by the American Board of Pharmacotherapy: Therapy (medical treatment) using Preventative Medicine, a board certification in addiction pharmaceutical drugs. medicine from the American Board of Addiction Medicine, Recovery capital: The breadth and depth of internal a subspecialty board certification in addiction psychiatry and external resources that can be drawn upon to initiate and from the American Board of Psychiatry and Neurology, a sustain recovery from alcohol and other drug problems. It can subspecialty board certification in addiction medicine be found at the personal, social, community and cultural from the American Osteopathic Association, or certification levels. Examples of recovery capital include physical health, in addiction medicine from the American Society of Addic- financial assets, supportive social relationships, visible local tion Medicine. recovery role models, and accessible/affordable community 8 Adjunct therapy (see also monotherapy): A pharma- resources. ceutical drug used together with a primary pharmaceutical Substance use: Used instead of ‘‘drug use’’ or ‘‘drug drug whose purpose is to assist the primary treatment.1 and alcohol use,’’ this term refers to the use of psychotropic Alcohol Hallucinosis/Alcohol-induced Psychotic Dis- substances, which may include illegal drugs, medications or order: See Special Terms on page 16. alcohol. This does not refer to nicotine.3 ASAM Criteria dimensions: The ASAM Criteria use Substance Use Disorder (SUD): Substance use disor- six dimensions to define a holistic biopsychosocial assess- der is marked by a cluster of cognitive, behavioral, and ment of an individual to be used for service and treatment
Recommended publications
  • Inhalants Booklet6/4/0712:04Ampage1 Inhalants Inhalants Booklet 6/4/07 12:04 AM Page 2

    Inhalants Booklet6/4/0712:04Ampage1 Inhalants Inhalants Booklet 6/4/07 12:04 AM Page 2

    inhalants booklet6/4/0712:04AMPage1 inhalants inhalants booklet 6/4/07 12:04 AM Page 2 inhalants WHAT ARE INHALANTS? Inhalants are a range of products that are sniffed or inhaled to give the user an immediate head rush or ‘high’. These substances are easily absorbed through the lungs and carried to the brain, where they act to slow down the central nervous system. Many familiar household products are inhalants. Some of the most common are: • Glue • Aerosol spray cans • Cleaning fluids • Felt-tipped pens • Correction fluid (liquid paper) • Chrome-based paints • Paint or paint thinner • Petrol • Anaesthetics Many inhalants are classified as volatile solvents. These change rapidly from a liquid or semi-solid state to a gas when exposed to air. They include chemicals that are found in products such as deodorants, air fresheners, lighter fuels and propellant gases used in aerosols such as whipped cream dispensers. Some volatile solvents are inhaled because of the effects produced not only by the product’s main ingredient, but by the propellant gases, as in aerosols, such as hair spray. Other solvents found in aerosol products such as gold and silver spray paint are sniffed not because of the effects from propellant gases but because of the psychoactive effects caused by the specific solvents necessary to suspend these metallic paints in the spray. The sniffing of metallic paints is known as ‘chroming’. inhalants booklet 6/4/07 12:04 AM Page 3 Another category of inhalant is the nitrites. Amyl, butyl and isobutyl nitrite (collectively known as alkyl nitrites) are clear, yellow liquids which are inhaled for their intoxicating effects.
  • An Ecological Investigation of the Time Course of Hangover

    An Ecological Investigation of the Time Course of Hangover

    AN ECOLOGICAL INVESTIGATION OF HANGOVER SEVERITY AND TIME COURSE _______________________________________ A Dissertation presented to the Faculty of the Graduate School at the University of Missouri-Columbia _______________________________________________________ In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy _____________________________________________________ by ERIN HUNT-CARTER Dr. Thomas Piasecki, Dissertation Supervisor DECEMBER 2010 The undersigned, appointed by the dean of the Graduate School, have examined the dissertation entitled AN ECOLOGICAL INVESTIGATION OF HANGOVER SEVERITY AND TIME COURSE presented by Erin E. Hunt-Carter, a candidate for the degree of doctor of philosophy, and hereby certify that, in their opinion, it is worthy of acceptance. Professor Thomas M. Piasecki Professor Wendy S. Slutske Professor Kenneth J. Sher Professor Dennis K. Miller Professor Daniel C. Vinson Thank you to my wonderful husband, Brent. I would not have completed this without your endless encouragement and kindness. Thank you to my parents, Toni and John Hunt, and my parents-in-law, Sondra and Guy Carter. Their support and many hours of babysitting were invaluable. Thank you to my sister, Meghan Hunt, for being riotously funny and supporting me through this process. Finally, I’d like to thank my children, Ian and Anna Carter, for keeping me grounded and reminding me what is truly important in life. ACKNOWLEDGEMENTS It is a pleasure to thank those who made this dissertation possible. First, I would like to express my gratitude to my doctoral advisor, Dr. Thomas Piasecki. He generously welcomed me into his lab, and enabled me to gain invaluable experience with ecological momentary assessment. I could not have completed this dissertation without his patient advice, extensive knowledge, and encouragement.
  • Approach to Acute Ataxia in Childhood: Diagnosis and Evaluation Lalitha Sivaswamy, MD

    Approach to Acute Ataxia in Childhood: Diagnosis and Evaluation Lalitha Sivaswamy, MD

    FEATURE Approach to Acute Ataxia in Childhood: Diagnosis and Evaluation Lalitha Sivaswamy, MD opsoclonus myoclonus ataxia syndrome, must receive special mention because the underlying disease process may be ame- nable to surgical intervention. In the tod- dler- and school-age groups, certain condi- tions (such as stroke and acute cerebellitis) require immediate recognition and imag- ing, whereas others (such as post-infec- tious ataxia and concussion) require close follow-up. Finally, mention must be made of diseases outside of the central nervous system that can present with ataxia, such as Guillain-Barré syndrome. he word ataxia is derived from the Greek word ataktos, which T means “lack of order.” Ataxia is characterized by disturbances in the voluntary coordination of posture and movement. In children, it is most prominent during walking (the sine qua non being a staggering gait with impaired tandem), but it can also be present during sitting or standing, or © Shutterstock when the child is performing move- Abstract Lalitha Sivaswamy, MD, is Associate Profes- ments of the arms, legs, or eyes. sor of Pediatrics and Neurology, Department Ataxia refers to motor incoordination that is This review focuses on the etiol- of Neurology, Wayne State University School of usually most prominent during movement ogy and diagnostic considerations for Medicine; and Medical Director, Headache Clinic, or when a child is attempting to maintain a acute ataxia, which for the purposes of Children’s Hospital of Michigan. sitting posture. The first part of the review this discussion refers to ataxia with a Address correspondence to: Lalitha Sivas- focuses on the anatomic localization of symptom evolution time of less than wamy, MD, Department of Neurology, Wayne ataxia — both within the nervous system 72 hours.1 State University School of Medicine, Children’s and without — using a combination of his- Motor coordination requires sensory Hospital of Michigan, 3901 Beaubien, Detroit, MI torical features and physical findings.
  • Combined Exposure to Nicotine and Ethanol in Adolescent Mice Differentially Affects Anxiety Levels During Exposure, Short-Term, and Long-Term Withdrawal

    Combined Exposure to Nicotine and Ethanol in Adolescent Mice Differentially Affects Anxiety Levels During Exposure, Short-Term, and Long-Term Withdrawal

    Neuropsychopharmacology (2008) 33, 599–610 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org Combined Exposure to Nicotine and Ethanol in Adolescent Mice Differentially Affects Anxiety Levels during Exposure, Short-Term, and Long-Term Withdrawal ,1 1 1 1 Yael Abreu-Villac¸a* , Fernanda Nunes , Fabı´ola do E Queiroz-Gomes , Alex C Manha˜es and 1 Cla´udio C Filgueiras 1 ˆ ˆ Laborato´rio de Neurofisiologia, Departamento de Ciencias Fisiolo´gicas, Instituto de Biologia Roberto Alcantara Gomes, Centro Biome´dico, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil Smoking and consumption of alcoholic beverages are frequently associated during adolescence. This association could be explained by the cumulative behavioral effects of nicotine and ethanol, particularly those related to anxiety levels. However, despite epidemiological findings, there have been few animal studies of the basic neurobiology of the combined exposure in the adolescent brain. In the present work we assessed, through the use of the elevated plus maze, the short- and long-term anxiety effects of nicotine (NIC) and/or ethanol (ETOH) exposure during adolescence (from the 30th to the 45th postnatal day) in four groups of male and female C57BL/6 mice: (1) Concomitant NIC (nicotine free-base solution (50 mg/ml) in 2% saccharin to drink) and ETOH (ethanol solution (25%, 2 g/kg) i.p. injected every other day) exposure; (2) NIC exposure; (3) ETOH exposure; (4) Vehicle. C57BL/6 mice were selected, in spite of the fact that they present slower ethanol metabolism, because they readily consume nicotine in the concentration used in the present study.
  • Scientific Opinion

    Scientific Opinion

    SCIENTIFIC OPINION ADOPTED: DD Month YEAR doi:10.2903/j.efsa.20YY.NNNN 1 Evaluation of the health risks related to the 2 presence of cyanogenic glycosides in foods other than raw 3 apricot kernels 4 5 EFSA Panel on Contaminants in the Food Chain (CONTAM), 6 Margherita Bignami, Laurent Bodin, James Kevin Chipman, Jesús del Mazo, Bettina Grasl- 7 Kraupp, Christer Hogstrand, Laurentius (Ron) Hoogenboom, Jean-Charles Leblanc, Carlo 8 Stefano Nebbia, Elsa Nielsen, Evangelia Ntzani, Annette Petersen, Salomon Sand, Dieter 9 Schrenk, Christiane Vleminckx, Heather Wallace, Diane Benford, Leon Brimer, Francesca 10 Romana Mancini, Manfred Metzler, Barbara Viviani, Andrea Altieri, Davide Arcella, Hans 11 Steinkellner and Tanja Schwerdtle 12 Abstract 13 In 2016, the EFSA CONTAM Panel published a scientific opinion on the acute health risks related to 14 the presence of cyanogenic glycosides (CNGs) in raw apricot kernels in which an acute reference dose 15 (ARfD) of 20 µg/kg bw was established for cyanide (CN). In the present opinion, the CONTAM Panel 16 concluded that this ARfD is applicable for acute effects of CN regardless the dietary source. Estimated 17 mean acute dietary exposures to cyanide from foods containing CNGs did not exceed the ARfD in any 18 age group. At the 95th percentile, the ARfD was exceeded up to about 2.5-fold in some surveys for 19 children and adolescent age groups. The main contributors to exposures were biscuits, juice or nectar 20 and pastries and cakes that could potentially contain CNGs. Taking into account the conservatism in 21 the exposure assessment and in derivation of the ARfD, it is unlikely that this estimated exceedance 22 would result in adverse effects.
  • Alcohol Sensitivity As an Endophenotype of Alcohol Use Disorder: Exploring Its Translational Utility Between Rodents and Humans

    Alcohol Sensitivity As an Endophenotype of Alcohol Use Disorder: Exploring Its Translational Utility Between Rodents and Humans

    brain sciences Review Alcohol Sensitivity as an Endophenotype of Alcohol Use Disorder: Exploring Its Translational Utility between Rodents and Humans Clarissa C. Parker 1,*, Ryan Lusk 2 and Laura M. Saba 2,* 1 Department of Psychology and Program in Neuroscience, Middlebury College, Middlebury, VT 05753, USA 2 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; [email protected] * Correspondence: [email protected] (C.C.P.); [email protected] (L.M.S.) Received: 3 September 2020; Accepted: 9 October 2020; Published: 13 October 2020 Abstract: Alcohol use disorder (AUD) is a complex, chronic, relapsing disorder with multiple interacting genetic and environmental influences. Numerous studies have verified the influence of genetics on AUD, yet the underlying biological pathways remain unknown. One strategy to interrogate complex diseases is the use of endophenotypes, which deconstruct current diagnostic categories into component traits that may be more amenable to genetic research. In this review, we explore how an endophenotype such as sensitivity to alcohol can be used in conjunction with rodent models to provide mechanistic insights into AUD. We evaluate three alcohol sensitivity endophenotypes (stimulation, intoxication, and aversion) for their translatability across human and rodent research by examining the underlying neurobiology and its relationship to consumption and AUD. We show examples in which results gleaned from rodents are successfully integrated with information from human studies to gain insight in the genetic underpinnings of AUD and AUD-related endophenotypes. Finally, we identify areas for future translational research that could greatly expand our knowledge of the biological and molecular aspects of the transition to AUD with the broad hope of finding better ways to treat this devastating disorder.
  • Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum

    Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum

    International Journal of Environmental Research and Public Health Review Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum Hiroshi Mitoma 1,* , Mario Manto 2,3 and Aasef G. Shaikh 4 1 Medical Education Promotion Center, Tokyo Medical University, Tokyo 160-0023, Japan 2 Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000 Charleroi, Belgium; [email protected] 3 Service des Neurosciences, University of Mons, 7000 Mons, Belgium 4 Louis Stokes Cleveland VA Medical Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44022, USA; [email protected] * Correspondence: [email protected] Abstract: Ethanol consumption remains a major concern at a world scale in terms of transient or irreversible neurological consequences, with motor, cognitive, or social consequences. Cerebellum is particularly vulnerable to ethanol, both during development and at the adult stage. In adults, chronic alcoholism elicits, in particular, cerebellar vermis atrophy, the anterior lobe of the cerebellum being highly vulnerable. Alcohol-dependent patients develop gait ataxia and lower limb postural tremor. Prenatal exposure to ethanol causes fetal alcohol spectrum disorder (FASD), characterized by permanent congenital disabilities in both motor and cognitive domains, including deficits in general intelligence, attention, executive function, language, memory, visual perception, and commu- nication/social skills. Children with FASD show volume deficits in the anterior lobules related to sensorimotor functions (Lobules I, II, IV, V, and VI), and lobules related to cognitive functions (Crus II and Lobule VIIB). Various mechanisms underlie ethanol-induced cell death, with oxidative stress and Citation: Mitoma, H.; Manto, M.; Shaikh, A.G. Mechanisms of endoplasmic reticulum (ER) stress being the main pro-apoptotic mechanisms in alcohol abuse and Ethanol-Induced Cerebellar Ataxia: FASD.
  • Caffeine and Adenosine

    Caffeine and Adenosine

    Journal of Alzheimer’s Disease 20 (2010) S3–S15 S3 DOI 10.3233/JAD-2010-1379 IOS Press Review Article Caffeine and Adenosine Joaquim A. Ribeiro∗ and Ana M. Sebastiao˜ Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of Neurosciences, Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal Abstract. Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas. In consequence, caffeine, when acting as an AR antagonist, is doing the opposite of activation of adenosine receptors due to removal of endogenous adenosinergic tonus. Besides AR antagonism, xanthines, including caffeine, have other biological actions: they inhibit phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promote calcium release from intracellular stores, and interfere with GABA-A receptors. Caffeine, through antagonism of ARs, affects brain functions such as sleep, cognition, learning, and memory, and modifies brain dysfunctions and diseases: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy, Pain/Migraine, Depression, Schizophrenia. In conclusion, targeting approaches that involve ARs will enhance the possibilities to correct brain dysfunctions, via the universally consumed substance that is caffeine. Keywords: Adenosine, Alzheimer’s disease, anxiety, caffeine, cognition, Huntington’s disease, migraine, Parkinson’s disease, schizophrenia, sleep INTRODUCTION were considered out of the scope of the present work. For more detailed analysis of the actions of caffeine in Caffeine causes most of its biological effects via humans, namely cognition, dementia, and Alzheimer’s antagonizing all types of adenosine receptors (ARs).
  • Diazepam and Kava Combination Article

    Diazepam and Kava Combination Article

    Journal of Advanced Research (2014) 5, 587–594 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Enhanced efficacy and reduced side effects of diazepam by kava combination Rasha A. Tawfiq a, Noha N. Nassar b,*, Wafaa I. El-Eraky c, Ezzeldein S. El-Denshary b a Egyptian Patent Office, Academy of Scientific Research and Technology, 101 Kasr El-Eini St., Cairo, Egypt b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Eini St., Cairo, Egypt c Department of Pharmacology, National Research Center, El-Tahrir St., Giza, Egypt ARTICLE INFO ABSTRACT Article history: The long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com- Received 2 April 2013 binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul- Received in revised form 18 July 2013 sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam Accepted 15 August 2013 (DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups Available online 22 August 2013 as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii) received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received Keywords: (iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/ Kava kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock Diazepam seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both Anticonvulsant acute and chronic treatment.
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor

    The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor

    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
  • Drinking and Driving and Underage

    Drinking and Driving and Underage

    Southern Pines Police Department Safety Tips Drinking & Driving Underage Consumption Help prevent driving under the influence of alcohol. The life you save may be someone you care about, might be your neighbor, or maybe even YOU! We need to remember the simple fact that alcohol is a drug. Alcohol is a depressant and greatly affects ones' ability to operate a motor vehicle or machinery safely. The formula for intoxication is rather easy to comprehend. A person who weighs about 150 pounds and then consumes a 12 ounce bottle of domestic beer, a 6 ounce glass of wine, or a 1 ounce shot of 90 proof whiskey will have a blood alcohol content (BAC) of about .02% if tested within one hour. Remember the limit for Driving While Impaired (DWI) is .08% BAC (.04% if driving a Commercial Motor Vehicle), which is usually 3 standard drinks within an hour. This places the person’s blood alcohol content over the DWI limit. Someone with a BAC limit of .05% is 50% more likely to be involved in a car crash. The potential for crashes increas as the level of intoxication increases. Don't let this happen to you or someone you know. Help keep our roads safe, know “when to say when”, and drive sober. Use a designated driver and be a friend – don’t let others drive if they have been drinking. Be aware of impairment through drugs or medication. Even prescription medication can affect the ability to drive and be safe. Follow all warning labels on medications and do not drive until you are aware of how you will react to the medication.
  • Efficacy of the Ria Treatment Platform: the First 230 Patients

    Efficacy of the Ria Treatment Platform: the First 230 Patients

    Efficacy of the Ria Treatment Platform The First 230 Patients John Mendelson MD1,2, Mary Mitchell PhD2, Jan Gryczynski PhD2, Steven Carswell PhD2, Robert Schwartz MD2 Ria Health1, San Francisco, CA and Friends Research Institute2, Baltimore MD Abstract How it works Clinician Facing Screenshot Legend Aim: To investigate longitudinal trends in blood alcohol content (BAC) assessments during a novel telehealth treatment for alcohol use disorder. Each visualization shows the progress of Ria Health patients in the treatment program Background: Despite available, efficacious treatments for alcohol use disorder Legend All data is based on objective measurement of BAC collected using the integrated bluetooth (AUD), only 6.7% of the 15.1 million people diagnosed with AUD in 2015 sought breathalyzer. treatment. Barriers such as stigma and lack of transportation make telemedicine X-axis is “Day in Treatment”: negative days are the baseline period (pre medication) starting by smartphone an attractive alternative. The Ria Health platform is a telemedicine at day -7 and progressing to day -1, positive days start with the first day on craving- program and smartphone app to help people with AUD decrease their alcohol reduction medications which is when the full set of Ria Health treatment interventions are consumption. Patients access a physician, obtain medication to curb alcohol underway: technology supported at-home medical management, coaching to assist in cravings, and receive support from a recovery coach. As part of the behavior modification, objective measurement and feedback, and social support. program patients track their BAC through daily breathalyzer assessments linked to their smartphones. Y-axis is a 28-day moving average of the metric.